Literature DB >> 24908242

Ileal effect on blood glucose, HbA1c, and GLP-1 in Goto-Kakizaki rats.

Henry Buchwald1, Hector J Menchaca, Van N Michalek, Nestor T Bertin.   

Abstract

BACKGROUND: There have been enumerable studies on the effects of glucagon-like peptide-1 (GLP-1) on satiety and pancreatic islet function, stimulating the advocacy of surgical transposition of the ileum (rich in GLP-1-generating L-cells) higher in the gastrointestinal tract for earlier stimulation. In the Goto-Kakizaki rat with naturally occurring type 2 diabetes, we studied the influence of ileal exclusion (IE) and ileal resection (IR) on blood glucose, hemoglobin A1c (HbA1c), and GLP-1.
METHODS: In six control (Ctrl), 10 IE, and 10 IR rats, over 12 weeks of follow-up, we determined blood glucose, HbA1c, and GLP-1.
RESULTS: Two animals in the IE and IR groups did not survive to week 13. Both operated groups weighed more than the Ctrl group at baseline and at 13 weeks; thus, IE and IR did not retard weight gain (p < 0.05). All three groups were equally hyperglycemic at week 13: 255 ± 10.2 Ctrl, 262 ± 11.0 IE, 292 ± 17.8 IR (mg/dl ± SEM). The three groups had statistically identical markedly elevated HbA1c percentages at week 13: 14.7 ± 28 Ctrl, 11.7 ± 3.4 IE, 13.8 ± 3.5 IR (% ± SEM). The end-study GLP-1 values (pM ± SEM) were 5 ± 0.9 Ctrl, 33 ± 8.9 IE, and 25 ± 6.7 IR. P values for intergroup differences were IE vs. Ctrl 0.02, IR vs. Ctrl 0.02, and IE vs. IR 0.59.
CONCLUSIONS: Neither IE nor IR resulted in a decrease in the mean GLP-1 level. On the contrary, the exclusion or resection of the L-cell rich ileum raised GLP-1 levels 5- to 6-fold. This increase in the GLP-1 was not associated with the mitigation of hyperglycemia or elevated HbA1c levels.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24908242     DOI: 10.1007/s11695-014-1307-x

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  37 in total

1.  Evidence for regulation of peptide-YY release by the proximal gut.

Authors:  G H Greeley; Y J Jeng; G Gomez; T Hashimoto; F L Hill; K Kern; T Kurosky; H F Chuo; J C Thompson
Journal:  Endocrinology       Date:  1989-03       Impact factor: 4.736

2.  Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias.

Authors:  Henry Buchwald; Kyle D Rudser; Stanley E Williams; Van N Michalek; James Vagasky; John E Connett
Journal:  Ann Surg       Date:  2010-06       Impact factor: 12.969

3.  Prevention of experimental atherosclerosis by ileal bypass: 20 per cent cholesterol diet and I-131 induced hypothyroidism in dogs.

Authors:  H W Scott; S E Stephenson; R Younger; B B Carlisle; S W Turney
Journal:  Ann Surg       Date:  1966-05       Impact factor: 12.969

4.  Distribution and immunocytochemical colocalization of peptide YY and enteroglucagon in endocrine cells of the rabbit colon.

Authors:  O Nilsson; A J Bilchik; J R Goldenring; G H Ballantyne; T E Adrian; I M Modlin
Journal:  Endocrinology       Date:  1991-07       Impact factor: 4.736

5.  GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans.

Authors:  E Näslund; J Bogefors; S Skogar; P Grybäck; H Jacobsson; J J Holst; P M Hellström
Journal:  Am J Physiol       Date:  1999-09

6.  Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias.

Authors:  H Buchwald; R L Varco; J R Boen; S E Williams; B J Hansen; C T Campos; G S Campbell; M B Pearce; A E Yellin; W A Edmiston; R D Smink; H S Sawin
Journal:  Arch Intern Med       Date:  1998-06-08

7.  Neural regulation of peptide YY secretion.

Authors:  T Zhang; T Uchida; G Gomez; F Lluis; J C Thompson; G H Greeley
Journal:  Regul Pept       Date:  1993-11-03

8.  Characterization of peptide-YY release in response to intracolonic infusion of amino acids.

Authors:  T Zhang; P L Brubaker; J C Thompson; G H Greeley
Journal:  Endocrinology       Date:  1993-02       Impact factor: 4.736

9.  Ileal transposition controls diabetes as well as modified duodenal jejunal bypass with better lipid lowering in a nonobese rat model of type II diabetes by increasing GLP-1.

Authors:  Tian Tian Wang; San Yuan Hu; Hai Dong Gao; Guang Yong Zhang; Chong Zhong Liu; Jin Bo Feng; Eldo E Frezza
Journal:  Ann Surg       Date:  2008-06       Impact factor: 12.969

10.  A comparison of intraduodenally and intracolonically administered nutrients on the release of peptide-YY in the dog.

Authors:  G H Greeley; T Hashimoto; M Izukura; G Gomez; J Jeng; F L Hill; F Lluis; J C Thompson
Journal:  Endocrinology       Date:  1989-10       Impact factor: 4.736

View more
  4 in total

1.  Putting the Hindgut Hypothesis to the Test in a Diabetic Zucker Rat Model.

Authors:  Claudia Laessle; Ke Jin; Gabriel J Seifert; Sylvia Timme-Bronsert; Stefan Fichtner-Feigl; Goran Marjanovic; Jodok Matthias Fink
Journal:  Obes Surg       Date:  2019-12       Impact factor: 4.129

2.  Common Channel Length in Bypass Surgery Does Not Impact T2DM in Diabetic Zucker Rats.

Authors:  Claudia Laessle; Sven Michelmichel; Goran Marjanovic; Simon Kuesters; Gabriel Seifert; Ulrich T Hopt; Jodok Matthias Fink
Journal:  Obes Surg       Date:  2017-08       Impact factor: 4.129

3.  Duodenal Exclusion but Not Sleeve Gastrectomy Preserves Insulin Secretion, Making It the More Effective Metabolic Procedure.

Authors:  Claudia Laessle; Gergana Nenova; Goran Marjanovic; Gabriel Seifert; Lampros Kousoulas; Bernd Jaenigen; Stefan Fichtner-Feigl; Jodok Matthias Fink
Journal:  Obes Surg       Date:  2018-05       Impact factor: 4.129

Review 4.  Review of Pharmacokinetic Data of Different Drug Classes in Goto-Kakizaki Rats, a Non-obese Model for Type 2 Diabetes Mellitus: Case Studies and Perspectives.

Authors:  Harilal Patel; Poonam Giri; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.